LAB Q3 2022 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q3 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$26M-10.0% YoY

Gross Profit

$9M36.0% margin

Operating Income

-$29M-113.2% margin

Net Income

-$29M-114.7% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+36.6%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$415M

Total Liabilities

$478M

Stockholders' Equity

-$63M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$29M	-10.0%
Gross Profit	$9M	$14M	-32.5%
Operating Income	-$29M	-$20M	-48.0%
Net Income	-$29M	-$14M	-112.6%

Revenue Segments

Product

$19M77%

Service

$6M23%

Geographic Segments

Americas

$11M43%

EMEA

$8M31%

Asia Pacific

$6M25%